Liquidia Corporation Common Stock
LQDALiquidia Corporation (LQDA) is a biotechnology company focused on the development and commercialization of innovative products using its proprietary PRINT (Particle Replication in Non-wetting Templates) technology. The company's primary areas of interest include treatments in the fields of pulmonary, infectious, and other specialized diseases. Liquidia aims to improve drug delivery and therapeutic outcomes through its advanced particle engineering platform.
Company News
The interstitial lung disease market is projected to grow at a CAGR of 8.7% from 2026-2036, driven by emerging therapies and pipeline candidates. The market was valued at USD 6 billion in 2025 across seven major markets, with the US accounting for 83% of the market. Key developments include FDA approval of nerandomilast (JASCAYD) for progressive ...
Liquidia Corporation's Board Chairman Stephen Bloch sold 70,234 shares worth $2.53 million in March 2026. However, the article suggests this is not a red flag for investors, as Bloch retained over 2 million shares and the sale represents only 3.02% of his holdings. The transaction appears to reflect liquidity management rather than loss of confid...
Liquidia's Chief Commercial Officer Scott Moomaw sold 80,000 shares worth approximately $2.8 million on March 9, 2026, representing 29.74% of his direct holdings. The sale was executed through a pre-arranged trading plan and appears to be routine liquidity management rather than a loss of confidence. Moomaw retained 188,954 shares and 25,300 stoc...
Liquidia Corporation will present two oral presentations at the CHEST 2025 annual meeting, focusing on clinical data from its ASCENT trial for LIQ861 DPI treprostinil in pulmonary hypertension-interstitial lung disease (PH-ILD) patients, highlighting safety and exploratory efficacy data.
The Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD) market is expected to grow significantly between 2025-2034, driven by improved diagnostic techniques, disease recognition, and emerging therapies targeting functional improvement and disease progression.
